C. Ndiaye, M. Mena, L. Alemany, M. Arbyn, X. Castellsagué et al., E6/E7 mRNA, and p16 INK4a detection in head and neck cancers: a systematic review and meta-analysis, Lancet Oncol, vol.15, pp.1319-1350, 2014.

K. K. Ang, J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal et al., Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, vol.363, pp.24-35, 2010.

M. Taberna, A. J. Rullan, C. Hierro, V. Navarro, S. Vazquez et al., Late toxicity after radical treatment for locally advanced head and neck cancer, Oral Oncol, vol.51, pp.795-804, 2015.

L. Masterson, D. Moualed, A. Masood, R. C. Dwivedi, R. Benson et al., De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma, Eur J Cancer, vol.50, pp.2636-2684, 2014.

M. Taberna, M. Marisa, M. A. Pavón, L. Alemany, M. L. Gillison et al., Human papillomavirus related oropharyngeal cancer, Ann Oncol, vol.28, pp.2386-98, 2017.

S. Kalyankrishna and J. R. Grandis, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol, vol.24, 2006.

H. Mirghani, F. Amen, F. Moreau, J. Guigay, D. M. Hartl et al., Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status, Eur J Cancer, vol.50, pp.1100-1111, 2014.

M. S. Lawrence, C. Sougnez, L. Lichtenstein, K. Cibulskis, E. Lander et al., Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, vol.517, pp.576-82, 2015.

G. Aquino, G. Pannone, A. Santoro, G. Liguori, R. Franco et al., PEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations, Cancer Biol Ther, vol.13, pp.967-77, 2012.

K. Ang, B. Berkey, X. Tu, H. Zhang, R. Katz et al., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res, vol.62, pp.7350-7356, 2002.

L. Monteiro, S. Ricardo, M. Delgado, F. Garcez, B. Do-amaral et al., Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas, Oral Dis, vol.20, pp.178-85, 2014.

H. Zur-hausen, Papillomaviruses and cancer: from basic studies to clinical application, Nat Rev Cancer, vol.2, pp.342-50, 2002.

H. S. Um, N. Mundi, J. Yoo, D. A. Palma, K. Fung et al., Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer, J Clin Virol, vol.61, pp.94-100, 2014.

D. Dimaio and L. M. Petti, The E5 proteins, Virology, vol.445, pp.99-114, 2013.

P. Leechanachai, L. Banks, F. Moreau, and G. Matlashewski, The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus, Oncogene, vol.7, pp.19-25, 1992.

S. W. Straight, B. Herman, and D. J. Mccance, The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes, J Virol, vol.69, pp.3185-92, 1995.

M. Mena, M. Taberna, S. Tous, S. Marquez, O. Clavero et al., Double positivity for HPV-DNA/p16 ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients, Oral Oncol, vol.78, pp.137-144, 2018.

X. Castellsagué, L. Alemany, M. Quer, G. Halec, B. Quirós et al., HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients, J Natl Cancer Inst, vol.108, p.403, 2016.

G. Halec, D. Holzinger, M. Schmitt, C. Flechtenmacher, G. Dyckhoff et al., Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma, Br J Cancer, vol.109, pp.172-83, 2013.

G. Larsen, C. Gyldenløve, M. Jensen, D. H. Therkildsen, M. H. Kiss et al., Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review, Br J Cancer, vol.110, pp.1587-94, 2014.

E. S. Prigge, M. Arbyn, V. K. Doeberitz, M. Reuschenbach, and M. , Diagnostic accuracy of p16 INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis, Int J Cancer, vol.140, pp.1186-98, 2017.

L. Alemany, M. Saunier, I. Alvarado-cabrero, B. Quirõs, J. Salmeron et al., Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide, Int J Cancer, vol.136, pp.98-107, 2015.

R. C. Jordan, M. W. Lingen, B. Perez-ordonez, X. He, R. Pickard et al., Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials, Am J Surg Pathol, vol.36, pp.945-54, 2012.

Z. Vojtechova, I. Sabol, M. Salakova, L. Turek, M. Grega et al., Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis, Int J Cancer, vol.138, pp.386-95, 2016.

M. Parfenov, C. S. Pedamallu, N. Gehlenborg, S. S. Freeman, L. Danilova et al., Characterization of HPV and host genome interactions in primary head and neck cancers, Proc Natl Acad Sci, vol.111, pp.15544-15553, 2014.

E. A. Mesri, M. A. Feitelson, and K. Munger, Human viral oncogenesis: a cancer hallmarks analysis, Cell Host Microbe, vol.15, pp.266-82, 2014.

R. Nicholson, J. M. Gee, and M. Harper, EGFR and cancer prognosis, Eur J Cancer, vol.37, pp.9-15, 2001.

D. N. Hayes, C. Van-waes, and T. Y. Seiwert, Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors, J Clin Oncol, vol.33, pp.3227-3261, 2015.

M. K. Keck, Z. Zuo, A. Khattri, T. P. Stricker, C. D. Brown et al., Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes, Clin Cancer Res, vol.21, pp.870-81, 2015.

B. Kumar, K. G. Cordell, J. S. Lee, F. P. Worden, M. E. Prince et al., Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer, J Clin Oncol, vol.26, pp.3128-3165, 2008.

M. Romanitan, A. Näsman, E. Munck-wikland, T. Dalianis, and T. Ramqvist, EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer, Anticancer Res, vol.33, pp.1575-84, 2013.

C. H. Chung, K. Ely, L. Mcgavran, M. Varella-garcia, J. Parker et al., Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas, J Clin Oncol, vol.24, pp.4170-4176, 2006.

R. J. Young, D. Rischin, R. Fisher, G. A. Mcarthur, S. B. Fox et al., Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma, Cancer Epidemiol Biomarkers Prev, vol.20, pp.1230-1237, 2011.

P. Bossi, C. Resteghini, N. Paielli, L. Licitra, S. Pilotti et al., Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma, Oncotarget, vol.7, pp.74362-79, 2016.

C. Fakhry, Q. Zhang, P. F. Nguyen-tan, D. Rosenthal, A. El-naggar et al., RTOG Ret 0129/0522 recurrence and HPV status: human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma, J Clin Oncol, vol.32, pp.3365-73, 2014.

J. Giralt, J. Trigo, S. Nuyts, M. Ozsahin, K. Skladowski et al., Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial, Lancet Oncol, vol.16, pp.221-253, 2015.

D. Ou, A. Levy, P. Blanchard, F. Nguyen, I. Garberis et al., Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role?, Oral Oncol, vol.59, pp.50-57, 2016.

H. Mehanna, M. Robinson, A. Hartley, A. Kong, B. Foran et al., Radiotherapy plus cisplatin or cetuximab in lowrisk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial, Lancet, 2018.

, National Cancer Institute press, 2018.

M. L. Gillison, A. M. Trotti, J. Harris, A. Eisbruch, P. M. Harari et al., Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial, Lancet, 2018.